BPC-157 vs Tretinoin
Extensively Studied vs FDA Approved
synergistic Mechanism-based · 50% BPC-157 and Tretinoin complement each other — angiogenesis delivers blood flow to support tissue healing. A natural pairing for injury recovery.
Molecular Data
BPC-157 Tretinoin
Weight 1,419.53 Da 300.44 Da
Half-life <30 minutes 0.5-2 hours (topical, local skin metabolism)
Chain 15 amino acids —
Type Pentadecapeptide Endogenous retinoid (vitamin A metabolite)
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Tretinoin
01 Reduces fine lines and wrinkles with consistent long-term use (strongest evidence of any topical)
02 Stimulates new collagen synthesis (procollagen I and III) in photoaged skin
03 Accelerates epidermal cell turnover, improving skin texture and smoothness
04 Reduces mottled hyperpigmentation and evens skin tone
05 FDA-approved treatment for acne vulgaris with over 50 years of clinical use
06 Treats and prevents comedonal and inflammatory acne by normalizing follicular keratinization
07 Enhances penetration and efficacy of other active skincare ingredients
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Tretinoin
0.025-0.05% cream or gel, applied nightly / Once daily (evening)
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Tretinoin
Peeling and flaking (retinoid dermatitis), especially in the first 2-6 weeks
Erythema (redness) and skin irritation at the application site
Dryness and tightness of the skin
Increased photosensitivity (heightened susceptibility to sunburn)
Initial acne purging (transient worsening of breakouts in weeks 2-6)
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Pregnancy and women planning to become pregnant (tretinoin is a known teratogen; oral retinoids cause severe birth defects, and while topical absorption is minimal, it is contraindicated as a precaution)
Breastfeeding (safety not established for topical tretinoin during lactation)
Known hypersensitivity to tretinoin, other retinoids, or any formulation excipients
Active eczema, rosacea, or severely compromised skin barrier at the application site
Concurrent use of other strong topical irritants without medical supervision (e.g., benzoyl peroxide at high concentrations on the same area at the same time)
Research Evidence
BPC-157 Tretinoin
Status Extensively Studied FDA Approved
References 8 studies 5 studies
Latest July 2025 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.